Articles and Publications

2017 (Apr., 2017~ Mar.,2018)

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.
The New England Journal of Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645

Effectiveness of Fulvestrant in Advanced or Metastatic Breast Cancer Patients in the Real World: A Retrospective Multi-center Cohort Study with 1072 Patients (JBCRG-C06; Safari)

H Kawaguchi, N Masuda, T Nakayama, K Aogi, K Anan, Y Ito, S Ohtani, N Sato, S Saji, E Tokunaga, S Nakamura, Y Hasegawa, M Hattori, T Fujisawa, S Morita, M Yamaguchi, T Yamashita, Y Yamamoto, S Ohno, and M Toi.
Breast Cancer Research and Treatment 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23.

2015 (Apr., 2015~ Mar.,2016)

Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
Breast Cancer 2015 Nov;22(6):586-95.
SpringerLink / Download (PDF)

Prognostic significance of subtype and pathologic response in operable breast cancer: a pooled analysis of prospective neoadjuvant studies of JBCRG

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
Breast Cancer (2015) 22:486-495

Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)

Hiroyasu Yamshiro · Hiroji Iwata · Norikazu Masuda · Naohito Yamamoto · Reiki Nishimura · Shoichiro Ohtani · Nobuaki Sato · Masato Takahashi · Takako Kamio · Kosuke Yamazaki · Tsuyoshi Saito · Makoto Kato · Tecchuu Lee · Shinji Ohno · Katsumasa Kuroi · Toshimi Takano · Masahiro Takada · Shinji Yasuno · Satoshi Morita · Masakazu Toi
International Journal of Clinical Oncology
Volume 20, Issue 4 (2015), Page 709-722

2014 (Apr., 2014~ Mar.,2015)

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

N. Masuda · K. Higaki · T. Takano · N. Matsunami · T. Morimoto · S. Ohtani · M. Mizutani · T. Miyamoto · K. Kuroi · S. Ohno · S. Morita · M. Toi
Cancer Chemotherapy and Pharmacology. (2014 Aug)
74(2):229-38. doi: 10.1007/s00280-014-2492-y

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

M. Takada, H. Ishiguro, S. Nagai, S. Ohtani, H. Kawabata, Y. Yanagita, Y. Hozumi, C. Shimizu, S. Takao, N. Sato, Y. Kosaka, Y. Sagara, H. Iwata, S. Ohno, K. Kuroi, N. Masuda, H. Yamashiro, M. Sugimoto, M. Kondo, Y. Naito,H. Sasano, T. Inamoto, S. Morita, & M. Toi on behalf of the JBCRG-C03 Collaborative Group
Breast Cancer Research and Treatment

Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer -BOOSTER trial, a multicenter randomized phase II study- JBCRG-M04 (BOOSTER)

Shigehira Saji, Masakazu Toi
CANCER BOARD Vol.7 N0.2 2014

2013 (Apr., 2013~ Mar.,2014)

Chugai Breast Cancer Press  Column

K.Kuroi
Feb 2014

Clinical Significance of ypT0/isypN0 as Pathologic Complete Response
-A Pooled Analysis of JBCRG-01, JBCRG-02, and JBCRG-03-

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
Japanese Journal of Breast Cancer Vol.28 No.6 2013

An Overview of the Japan Breast Cancer Research Group (JBCRG) activities

Shinji Ohno, Katsumasa Kuroi and Masakazu Toi
Breast Cancer. 2013 Mar 15. [Epub ahead of print]

The Current Status and Issues related to risk management of breast cancer patients receiving outpatient chemotherapy

Maiko Kanazawa, Norikazu Masuda, Katsumasa Kuroi, Kyoko Abe, Masakazu Toi; JBCRG (Japan Breast Cancer Research Group)
Japanese Journal of Breast Cancer Vol.28 2013

Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study

Yoshiki Mikami, Takayuki Ueno, Kenichi Yoshimura, Hitoshi Tsuda, Masafumi Kurosumi, Shinobu Masuda, Rie Horii, Masakazu Toi and Hironobu Sasano
Cancer Science November 2013 vol. 104 no. 11 1539–1543

2012 (Apr., 2012~ Mar.,2013)

Current status and vision of JBCRG (Japan Breast Cancer Research Group)

Norikazu Masuda, Masakazu Toi, Katsumasa Kuroi, etc.
Nyugan second edition, NihonRinsho 70, Extra number 7, p763-771, 2012

Neo-LaTH study; Dual-HER2 Blockage Therapy in HER2-Positive Breast Cancer (exploratory randomized P-II)

Norikazu Masuda, Masakazu Toi, Hiroi Kasai.
CANCER BOARD Breast Cancer 5(2):P.71-73、2012

2011 (Apr., 2011~ Mar.,2012)

Developing an international network for breast cancer research: the BIG experience

Clinical Investigation 1(5), 623-628, 2011

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey.

Kosuke Kawaguchi, Hiroshi Ishiguro, Satoshi Morita, Seigo Nakamura, Shinji Ohno, Norikazu Masuda, Hiroji Iwata, Kenjiro Aogi, Katsumasa Kuroi, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
Breast Cancer Research and Treatment, 130(2) : 627-634, 2011

Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer

Hiroji Iwata, Nobuaki Sato, Norikazu Masuda, Seigo Nakamura, Naohito Yamamoto, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Yasuo Ohashi, and Masakazu Toi
Japanese Journal of Clinical Oncology 41: 867-875, 2011

Back to Page Top

2010 (Apr., 2010~ Mar.,2011)

Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).

Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M.
Breast Cancer Res Treat. 2010 Nov 17. [Epub ahead of print]

ALTTO trial

Katsumasa Kuroi
Cancer Board Breast Cancer 1(1): 58, 2010

JBCRG-M02 trial

Katsumasa Kuroi
Cancer Board Breast Cancer 3(1): 91, 2010

JBCRG-07 trial

Norikazu Masuda
Cancer Board Breast Cancer 3(1): 92, 2010

Japan Breast Cancer Research Group (JBCRG)

Kuroi K, Kashiwa K, Toi M, Nakamura S, Iwata H, Ohno S, Masuda N, Aogi K, Sato N, Sasano H; Japan Breast Cancer Research Group (JBCRG)
Clinical Oncology 2010 Oct; 6(4): 360-368

Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population

Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; and the Japan Breast Cancer Research Group-Translational Research
Cancer 2010, July 1: 3113-3118

Back to Page Top

2009 (Apr., 2009~ Mar.,2010)

The new approach of the preoperative therapy for breast cancer – Steps of JBCRG study

Hiroyasu Yamashiro, Masakazu Toi
Igaku no ayumi Vol 230, No1,p57-61, 2009

SUPREMO(BIG2-04) Trial.

Katsumasa Kuroi
Cancer Board Breast Cancer 2(1): 68, 2009.

CREATE-X (JBCRG-04) Trial.

Norikazu Masuda
Cancer Board Breast Cancer 2(1) 70, 2009.

'Preoperative Chemotherapy ; Evaluation of Response' - Understanding of Breast Cancer: Basics and Clinics (Edited by Masakazu Toi)-

Katsumasa Kuroi
Iyaku(Medicine and Drug)Journal Co., Ltd., p654-662, 2009

An overview of JBCRG activities

Katsumasa Kuroi, Masakazu Toi
BIG newsletter volume 11 number 1 2009

Supremo trial expands into Asia

BIG newsletter volume 11 number 2 2009

Japan Breast Cancer Research Group (JBCRG)

Katsumasa Kuroi
European Society of Breast Cancer Specialists – Eusoma Newsletter 2009

Back to Page Top

2008 (Apr., 2008~ Mar.,2009)

Review of the study of FEC followed by docetaxel 100mg/m2 as preoperative chemotherapy in primary breast cancer

Seigo Nakamura, Norikazu Masuda, Hiroji Iwata, Masakazu Toi, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG).
Japanese Journal of Breast Cancer 2008, Vol.23,No.2 :p111-117

PhaseII study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival

Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, YamazakiK, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F,Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG)
Breast Cancer Res Treat. 2008 Aug;110(3):531-9. Epub 2007 Sep 19

Back to Page Top

2007 (Apr., 2007~ Mar.,2008)

Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)

Masuda N, Toi M, Takatsuka Y, Nakamura S, Iwata H, Ohno S, Kuroi K, Kusama M, Hisamatsu K, Yamazaki K, Eisei S, Sato Y, Kaise H, Kashiwaba M,Iwase H, Kurosumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Gan To Kagaku Ryoho. 2007 Oct; 34(10): 1609-15 (Japanese)

JBCRG03:Preoperative chemotherapy using Docetaxel 75 mg/m2, followed by FEC 100 mg/m2 - Review of and breakthrough by JBCRG01 and 02 -

Masahiro Kashiwaba, Go Wakabayashi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Norikazu Masuda, Nobuaki Sato, Taro Asaga, Naohito Yamamoto, Kenjiro Aogi, Yasuyuki Sato, Masafumi Kurozumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG)
Japanese Journal of Breast Cancer 2007,Vol.22 No.5, p372-375

Back to Page Top

2006 (Apr., 2006~ Mar.,2007)

Japan Breast Cacer Research Group (JBCRG) Trials Update.

Kuroi K, Toi M, Nakamura S, Iwata H, Ohno S, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG).
BIG NEWS LETTER 2006,8 (1)

Issues in the Assessment of the Pathologic Effect of Primary Systemic Therapy for Breast Cancer

Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Breast Cancer. 2005; 13(1): 38-48.

Back to Page Top

2005 (Apr., 2005~ Mar.,2006)

Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breastcarcinoma

Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y,Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG).
Breast Cancer. 2005;12(2):99-103.

Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer

Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother.2005 Oct;59 Suppl 2:S323-4.

Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.

Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.

From the Japan Breast Cancer Research Group (JBCRG): How to define pCR: Our Challenge.

Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).
BIG NEWS LETTER 2005, 7(1),

Back to Page Top